The discovery of Australia antigen and subsequent identification as the surface antigen of Hepatitis B virus (HBsAg) represents a significant breakthrough in the understanding of the disease. Screening of blood donors for the presence of this antigen in serum has significantly reduced the incidence of Hepatitis B in blood transfusion recipients. Furthermore, anti-HBsAg determination can be used to:
a) monitor the progress of patients recovering from Hepatitis B viral infection;
b) indicate if the patient has had prior immunological exposure to HBsAg;
c) study the epidemiological factors associated with transmission of HBsAg.

This HBsAg Rapid Test is a rapid, qualitative, one-step immunoassay employing a unique combination of monoclonal-dye conjugate (colloidal gold) and polyclonal solid phase antibodies to selectively identify HBsAg of Hepatitis B viral infection with a high degree of sensitivity. In this test, whole blood , plasma or serum specimen is added directly to the sample pad. As the test sample flows through the sample pad, the labelled antibody-dye conjugate binds to HBsAg forming an antibody-antigen complex. The pad is in contact with a chromatographic test strip which contains a region of immobilised polyclonal anti-HBsAg antibody in the test line. The antibody-antigen complex moves by capillary action along the strip forming a line of immobilised complex by the zone of antibody in the test line, indicating the presence of HBsAg in the sample (pink line). If no antigen is present, the test line will remain clear. The appearance of a pink line in the control line shows that the test has been carried out correctly.

Ordering Information:

• 1. Cassette Cat No.: AN1021C
• 2. Dipstick Cat No.: AN1021S

Helpful Documents:

• 1. Instruction for use
• 2. MSDS